Patents by Inventor Chrystelle Brignone
Chrystelle Brignone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330182Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: May 5, 2023Publication date: October 19, 2023Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20230272107Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation.Type: ApplicationFiled: May 5, 2023Publication date: August 31, 2023Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Patent number: 11684654Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: GrantFiled: October 16, 2020Date of Patent: June 27, 2023Assignee: IMMUTEP S.A.S.Inventors: Frederic Triebel, Chrystelle Brignone
-
Patent number: 11680104Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation. The antibodies may be used as medicaments, in particular for the treatment of conditions associated with proliferation and/or activation of CD4+ and/or CD8+ T cells, such as inflammatory and autoimmune disorders.Type: GrantFiled: September 1, 2016Date of Patent: June 20, 2023Assignee: IMMUTEP S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone
-
Publication number: 20230074746Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells).Type: ApplicationFiled: September 6, 2022Publication date: March 9, 2023Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20220341913Abstract: Assays for screening for, or determining activity of, an agonist of lymphocyte-activation gene 3 (LAG-3) are described. According to the assays, a plurality of effector T cells is provided, each effector T cell expressing LAG-3 and a T-cell receptor (TCR) on its surface, and comprising a reporter gene encoding a reporter, wherein expression of the reporter is regulated by LAG-3-mediated inhibition of TCR signaling within the effector T cells. Activity of the agonist is determined from the extent to which expression of the reporter is altered in the presence of the agonist compared with expression of the reporter in the absence of the agonist. The assays may be used for determining the potency of a preparation of the agonist as part of a quality control step in production of the agonist, or for stability testing of a preparation of the agonist. Kits for carrying out the assays are also described.Type: ApplicationFiled: May 1, 2020Publication date: October 27, 2022Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE, Mathieu ANGIN
-
Publication number: 20220220199Abstract: The present disclosure relates to agonistic anti-LAG-3 (CD223) antibodies which inhibit T cell receptor (TCR)-mediated signal transduction in LAG-3 positive T cells through agonism of LAG-3. The antibodies bind specifically to a discontinuous epitope within the extracellular lg superfamily domain D1 of LAG-3 protein, wherein the epitope lies outside a 30 amino acid extra-loop sequence of domain D1 of the LAG-3 protein. Use of the antibodies as medicaments is described.Type: ApplicationFiled: May 1, 2020Publication date: July 14, 2022Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20220153835Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: ApplicationFiled: September 30, 2021Publication date: May 19, 2022Inventors: Glenn DRANOFF, Frederic TRIEBEL, Chrystelle BRIGNONE, Walter A. BLATTLER, Jennifer Marie MATARAZA, Catherine Ann SABATOS-PEYTON, Hwai Wen CHANG, Gerhard Johann FREY
-
Publication number: 20210177937Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: October 16, 2020Publication date: June 17, 2021Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Patent number: 10940181Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: GrantFiled: January 3, 2020Date of Patent: March 9, 2021Assignee: IMMUTEP S.A.S.Inventors: Frederic Triebel, Chrystelle Brignone
-
Publication number: 20210009687Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: ApplicationFiled: June 9, 2020Publication date: January 14, 2021Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 10874713Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: GrantFiled: January 8, 2016Date of Patent: December 29, 2020Assignee: IMMUTEP S.A.S.Inventors: Frederic Triebel, Chrystelle Brignone
-
Patent number: 10711060Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: GrantFiled: December 1, 2017Date of Patent: July 14, 2020Assignees: NOVARTIS AG, Immutep S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Publication number: 20200121757Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: January 3, 2020Publication date: April 23, 2020Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20190153112Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation. The antibodies may be used as medicaments, in particular for the treatment of conditions associated with proliferation and/or activation of CD4+ and/or CD8+ T cells, such as inflammatory and autoimmune disorders.Type: ApplicationFiled: September 1, 2016Publication date: May 23, 2019Inventors: Frédéric TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20180340025Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: ApplicationFiled: July 28, 2016Publication date: November 29, 2018Applicants: Novartis AG, Immutep S.A.S.Inventors: Glenn Dranoff, Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Publication number: 20180271940Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: January 8, 2016Publication date: September 27, 2018Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20180086830Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: ApplicationFiled: December 1, 2017Publication date: March 29, 2018Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 9908936Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: GrantFiled: March 24, 2017Date of Patent: March 6, 2018Assignees: Novartis AG, Immutep S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Publication number: 20170210804Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: ApplicationFiled: March 24, 2017Publication date: July 27, 2017Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey